Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can brain scans and genetics predict autism and ADHD before symptoms appear?

NCT ID NCT07570381

Knowledge-focused Sponsor: University of Exeter Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking for early clues—like brain activity, genetics, and environment—that might predict autism, ADHD, and related mental health issues in children and young adults. Researchers will follow 800 participants from infancy through young adulthood across 10 international sites. The goal is to better understand these conditions and pave the way for personalized prevention and treatment strategies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will recruit approximately 800 participants from early infancy to young adulthood across 10 international sites. OS1 will include infants at increased neurodevelopmental risk: very or extremely preterm infants (\<32 or \<28 weeks), term-born infants with perinatal asphyxia or hypoxic-ischaemic encephalopathy, and a comparison group of term-born infants without risk factors. Infants are enrolled within the first 12 months and followed to 42 months. OS2 will include children (5-10 years), adolescents (11-18 years), and young adults (19-25 years) with confirmed diagnoses of ASD, ADHD, or DCD, conditions linked to elevated anxiety and depression risk. Recruitment aims for balanced sex representation and diverse socioeconomic and cultural backgrounds.

Ages

6 months to 25 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

OS1 Inclusion Criteria: * Infants born very preterm (\<32 weeks) or extremely preterm (\<28 weeks); or * Term-born infants with documented perinatal asphyxia and hypoxic-ischaemic encephalopathy (HIE); or * Term-born infants with no risk factors (comparison group). * Must be ≤12 months corrected age at enrolment. OS1 Exclusion Criteria: * Syndromic, chromosomal, or known genetic conditions. * Motor impairments that would prevent participation in psychometric or neurophysiology assessments. OS2 Inclusion Criteria: * Individuals aged 5-25 years. * Clinical diagnosis of ASD, ADHD, or Developmental Coordination Disorder (DCD). * Able to participate in scheduled assessments. OS2 Exclusion Criteria: * Severe motor impairments that limit psychometric assessment. * Diagnosis of schizophrenia, due to confounding neurocognitive effects.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD - attention deficit disorder with hyperactivity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder autism spectrum disorder developmental coordination disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADHD - attention deficit disorder with hyperactivity Autism spectrum disorder (ASD) Developmental coordination disorder (DCD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Exeter

    Exeter, EX4 4QJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.